Ascentage Pharma Group (AAPG) - Uzoq muddatli qarzning kapitalga nisbati
Ascentage Pharma Group (AAPG) narxlarining trayektoriyasi 1.17 ning joriy ko'rsatkichini namoyish etmoqda. Ushbu biotexnologiya kompaniyasining farovonligi o'simtaga qarshi agentlarning bozor tomonidan qabul qilinishiga, uning asosiy dori vositasining muvaffaqiyatiga va Takeda tomonidan ko'rsatilgan qo'llab-quvvatlashga bog'liq. Biomateriallar uchun uzluksiz transchegaraviy logistika tadqiqotlar uchun juda muhimdir; biroq, ulkan sinov xarajatlari va tartibga soluvchi qarorlar kutilayotgan bir paytda kelajakdagi daromadlar bo'yicha noaniqliklar sababli moliyaviy barqarorlik shubhali bo'lib qolmoqda.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_AAPG_-_Ascentage-Pharma-Group_-_Long-Term-Debt-to-Equity "ascentage.com (AAPG): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi 25.01.2025dan 30.10.2026gacha | 👁️GURU.Markets👁️")
Ascentage Pharma Group kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Ascentage Pharma Group|AAPG - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati ascentage.com|AAPG - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Ascentage Pharma Group|AAPG - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Ascentage Pharma|Tezkor likvidlik koeffitsiyenti ascentage.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
Kompaniyaning umumiy tahlili:Ascentage Pharma Group International - AAPG
Ascentage Pharma Group (AAPG) aktivlari uchun fundamental tayanchni aniqlash maqsadida, uzoq muddatli qarzlarning kapitalga nisbatini tahlil qilish juda muhimdir. Uzoq muddatli qarzning kapitalga nisbati onkologik dori vositalari uchun qimmatga tushadigan autsorsing asosidagi klinik sinovlarning moliyalashtirish barqarorligini aks ettiradi va bu biznesning to'lov qobiliyatini saqlash hamda beqaror bozor sikllari sharoitida intellektual mulkni himoya qilish imkoniyatini tasdiqlaydi.
Muhim raqobatchilar
Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati CG Oncology, Inc. CGON|URGN: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Bicara Therapeutics - Uzoq muddatli qarzning kapitalga nisbati|Personalis Inc (PSNL) - Uzoq muddatli qarzning o'z kapitaliga nisbati|ERAS: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Delcath Corp (DCTH)|Uzoq muddatli qarzning o'z kapitaliga nisbati Y-mAbs Therapeutics|AURA: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati SLS (SELLAS Life Sciences Group)|ACTU - Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR: Uzoq muddatli qarzning o'z kapitaliga nisbati|HURA - Uzoq muddatli qarzning kapitalga nisbati|Protara Therapeutics, Inc. (TARA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Fate Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati TScan TCRX|Uzoq muddatli qarzning kapitalga nisbati CSBR|Uzoq muddatli qarzning kapitalga nisbati xbiotech.com (XBIT)|Uzoq muddatli qarzning o'z kapitaliga nisbati CEL-SCI CVM|Uzoq muddatli qarzdorlikning kapitalga nisbati OS Therapies Inc. (OSTX)|Radiopharm Theranostics Limited - Uzoq muddatli qarzning kapitalga nisbati|Artiva Biotherapeutics, Inc. (ARTV) - Uzoq muddatli qarzning o'z kapitaliga nisbati|ANL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati verupharma.com (VERU)|Uzoq muddatli qarzning o'z kapitaliga nisbati Tempest Therapeutics, Inc.|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi XLO (Xilio)|Uzoq muddatli qarzning o'z kapitaliga nisbati RENB (Renovaro Inc.)|Uzoq muddatli kreditlarning kapitalga nisbati MURA|Uzoq muddatli qarzning kapitalga nisbati KAPA (Kairos Pharma)|Uzoq muddatli qarzning kapitalga nisbati OnKure Therapeutics, Inc. OKUR|CytoMed - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati Curis, Inc. (CRIS)|APLM: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Tharimmune Corporation (THAR)|Uzoq muddatli qarzning o'z kapitaliga nisbati ADVB|GNPX: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati Calidi Biotherapeutics (CLDI)|SBFM: Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga nisbati XBIO (Xenetic Biosciences, Inc.)|Uzoq muddatli qarzning kapitalga koeffitsiyenti SLRX|Purple Biotech - Uzoq muddatli qarzning kapitalga nisbati|AONC - Uzoq muddatli qarzning kapitalga nisbati|BeiGene (BGNE) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Checkpoint Therapeutics Inc. - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati Elevation Oncology, Inc.|Uzoq muddatli qarzning o'z kapitaliga nisbati iCAD Corp (ICAD)|Uzoq muddatli qarzning kapitalga nisbati IKNA|Uzoq muddatli qarzning kapitalga nisbati notablelabs.com (NTBL)|Viracta Therapeutics, Inc. - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti MOR|NAYA Bio - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati Ascentage (AAPGV)